# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Furthers Global Leadership in Donor Organ and Transplant Recipient HLA TypingCareDx, Inc. (NASDAQ:CDNA) – The Transplant Compan...
BTIG analyst Mark Massaro reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $22 price target.
BTIG analyst Mark Massaro reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $22 price target.
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, developme...
CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant so...
William Blair analyst Andrew Brackmann initiates coverage on CareDx (NASDAQ:CDNA) with a Market Perform rating.